Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA's Walks Fine Line On How It Will Publish Clinical Study Reports

This article was originally published in The Pink Sheet Daily

Executive Summary

In finalizing its policy on publishing clinical study reports, EMA stresses redactions of commercially confidential information will be rare, but critics still say it is favoring the pharma industry.

You may also be interested in...



EMA Loses Key Round In Court Battle For Flagship Transparency Policy

The European Medicines Agency may be forced to re-examine whether clinical trial data should be regarded as presumptively confidential under its access to documents policy.

European Notebook: Data Transparency And Adaptive Licensing Move Forward

More clinical trials move to Denmark, Sanofi’s Viehbacher moves to Boston, and analysts suggest thwarted Pfizer’s next strategic move may be to use contingent value rights in a future attempt for AstraZeneca, plus more in this month’s notebook.

MEPs Pass Clinical Trials Laws But Implementation Will Be Troublesome

Europe’s parliamentarians have unsurprisingly and overwhelmingly voted in favor of the Clinical Trials Regulation – but implementation and transparency problems hover on the horizon.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel